First human test of new drug candidate begins
NCT ID NCT06675565
Summary
This early-stage study tested a new drug called ALN-AGT01 RVR in healthy adults to see if it is safe and how it moves through the body. Forty-two participants received a single dose, and researchers closely monitored them for any side effects. The main goal was to gather initial safety data to see if the drug is suitable for further testing in people with medical conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Montreal, Canada
Conditions
Explore the condition pages connected to this study.